Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND/RATIONALE: Treatment of severe hypertriglyceridemia is indicated to reduce the risk of pancreatitis in patients with triglyceride (TG) levels > or =500 mg/dL. Hypertriglyceridemia is also a risk factor for atherosclerotic coronary heart disease. Prescription omega-3 fatty acids (P-OM3) and fenofibrate (FENO) are among the most effective lipid-altering agents that reduce TG levels. Given that some patients may not achieve optimal TG levels with a single agent, we hypothesized that concomitant use of P-OM3 or addition of P-OM3 to FENO would result in a TG reduction greater than that with FENO alone. METHODS: This randomized, 8-week, double-blind, placebo-controlled study was designed to compare the safety and efficacy of P-OM3 4 g QD plus concomitant FENO 130 mg with FENO 130 mg QD plus placebo in subjects with very high TG levels (> or =500 mg/dL). Subjects who completed the double-blind study were given the option to continue into an open-label, 8-week extension study, wherein they all received P-OM3 4 g plus FENO 130 mg QD. On completion of the first extension study, subjects were eligible to continue into an open-label 24-month extension of the treatment with P-OM3 4 g plus FENO 130 mg QD. RESULTS: Concomitant P-OM3 + FENO (n = 81) and FENO monotherapy (n = 82) reduced median TG values from 649.5 to 267.5 mg/dL (60.8%) and from 669.3 to 310 mg/dL (53.8%), respectively (P = 0.059). When subjects who had received 8 weeks of stable FENO monotherapy were given P-OM3 during the 8-week, open-label extension study (n = 58), TG levels were reduced 17.5% (P = 0.003) over the course of the extension. The second extension phase was terminated early (n = 93)-not because of a safety signal but because of the lack of a substantial incremental change in the primary endpoint lipid values above that reached in either the original study or the first extension in subjects receiving the combination of fenofibrate and P-OM3. CONCLUSIONS: Both FENO monotherapy and P-OM3 + FENO significantly reduced TGs in subjects with very high TGs, with a trend to greater reduction in the P-OM3 + FENO group. The addition of P-OM3 to stable FENO therapy in the same subjects in an open-label extension study resulted in a statistically significant reduction in TG levels. Subjects who received P-OM3 + FENO for 16 weeks and subjects in which P-OM3 was added to FENO monotherapy during the open-label phase of the study did not differ in their final lipid responses. In the second open-label extension, within the combined group taking P-OM3 and FENO, analysis of change from the second extension baseline to end of treatment revealed no clinically important change.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Six published trials in which 3 to 4 g/d n-3 FA was administered to people with HTG not taking other lipidlowering medications were identified as meeting the inclusion criteria listed above.”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [28]
In the citing paper
“In 2 older monotherapy studies of dietary supplements (providing 3 and 4.5 g/d total EPA+DHA) that included at least 50 people per arm, a 7% to 8% increase in LDL-C was reported (only marginally significant for the lower dose; P=0.054); however, these studies reported a 35% and 39% reduction in triglycerides. 28,31”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [28]
In the citing paper
“Indeed, effects on LDL-C were nonsignificant or marginally significant (1 study, P=0.052) in studies of 4 g/d O3AEE in which triglyceride reductions were ≤30%.26,28,[30][31][32][33]36,37”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [28]
In the citing paper
“Although most trials presented in Table 4 specified direct LDL-C measurement in cases when triglycerides >400 mg/dL (as is standard for clinical practice), only 3 trials reported LDL-C results obtained from direct LDL measurement throughout the triglyceride range.28,30,45”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [28]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Assmann, G., Schulte, H., & von Eckardstein, A. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00159-2 · Cited by 447 · cited 1×
“2% in subjects with TG levels in the range of 400 to 799 mg/dL, respectively.(2) Profound elevations in TG levels, reflecting elevated very low-density lipoproteins Received for publication January 16, 2009; accepted June 1, 2009.”
BackgroundIssues in Hyperlipidemic Pancreatitis
Yadav, D., & Pitchumoni, C. S. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200301000-00016 · Cited by 435 · cited 1×
“This situation is associated with genetic abnormalities that impair the metabolism of TG-rich lipoproteins (TRL), such as in patients with lipoprotein lipase deficiency.(3,4) Patients with very high TG levels, defined as $500 mg/dL, are at high risk for developing acute pancreatitis.”
BackgroundDavidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Self-citationSafety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306
Bays, H. E., Tighe, A. P., Sadovsky, R., & Davidson, M. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.391 · Cited by 265 · cited 3×
“Omega-3 fatty acids and fibrates significantly reduce TG levels by both limiting the secretion of VLDL and enhancing the conversion of VLDL to LDL particles.(6,7) Despite some similarity in their mechanism of action, the combination of fibrates and omega-3 fatty acids is often used to lower TG levels in subjects who a…”
BackgroundSelf-citation
Cited by
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
2023 Chinese guideline for lipid management
Li, J.-J., Zhao, S.-P., Zhao, D., Lu, G.-P., Peng, D.-Q., Liu, J., Chen, Z.-Y., Guo, Y.-L., Wu, N.-Q., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 223
Adiamah, A., Psaltis, E., Crook, M., & Lobo, D. N. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.028 · Cited by 175
“There are some studies proposing that dual therapy in these patients with hyperlipidaemia is more effective than monotherapy [72].”
BackgroundMethodFish Oil for the Treatment of Cardiovascular Disease
Weitz, D., Weintraub, H., Fisher, E., & Schwartzbard, A. Z. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ea0de0 · Cited by 138
“Therapy was well-tolerated without significant adverse reactions at 8 weeks or at the end of a 2-year open label extension.(64) The combination of fish oil and niacin requires further study.”
Background2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 128
Metadata
- Authors
- Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A.
- Affiliations
- Sterling Research Group (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- University of Missouri–Kansas City (US)
- Corresponding author
- Roth, Eli M
- Stein, Evan A
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2009-09
- Volume
- 54
- Issue
- 3
- Pages
- 196-203
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2070765163
- Cited by
- 32
- References
- 25
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 4 · 2022: 3 · 2019: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 3 · 2012: 3
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- fenofibrate, hypertriglyceridemia, triglyceride lowering, combination lipid-lowering therapy, pancreatitis risk, coronary heart disease risk, safety and tolerability, triglyceride levels, omega-3 supplementation, dyslipidemia management
- MeSH terms
- Adolescent, Adult, Aged, Hypolipidemic Agents, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Fenofibrate, Severity of Illness Index, Triglycerides, Hypertriglyceridemia, Fatty Acids, Omega-3, Diet Records, Body Mass Index, Diet, Fat-Restricted, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects. https://app.cochat.ai/papers/10.1097/fjc.0b013e3181b0cf71
- The paper
- Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009). Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0b013e3181b0cf71
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.